# Phase 1 carcinoma trials recruiting: 402 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 402 trials in phase 1 for carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 carcinoma trials: 402 rows for $20.10, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 402
- Recruiting or not yet: 402
- Read on: November 19, 2026

## Trials

The 25 newest of 402, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 16, 2026 | NCT07938463 | Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC | Dana-Farber Cancer Institute | Phase 1 | Not yet recruiting | ALK Positive Non-small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938463) |
| November 10, 2026 | NCT07929961 | Study of MC001 in Patients With Advanced Solid Tumours | National University Hospital, Singapore | Phase 1 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Nasopharyngeal Carcinoma, Advanced Solid Tumours | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929961) |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| November 5, 2026 | NCT07919509 | A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During... | University of Alabama at Birmingham | Phase 1 | Not yet recruiting | Cancer, Chemotherapy, Squamous Cell Carcinoma (SCC) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919509) |
| November 3, 2026 | NCT07912268 | Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912268) |
| November 2, 2026 | NCT07910942 | A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer | Kanvas Biosciences | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910942) |
| November 2, 2026 | NCT07908667 | A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer | Novartis Pharmaceuticals | Phase 1 | Recruiting | Extensive-stage Small Cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908667) |
| October 29, 2026 | NCT07905677 | Phase 1 Study of VT-101 in Advanced Ovarian Cancer | Sponsor not shown (see the record) | Phase 1 | Recruiting | Epithelial Ovarian Cancer, Ovarian Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905677) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 28, 2026 | NCT07901959 | Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia | Rockefeller University | Phase 1 | Recruiting | Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901959) |
| October 28, 2026 | NCT07899801 | A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | Non Small Cell Lung Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899801) |
| October 27, 2026 | NCT07899086 | A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899086) |
| October 27, 2026 | NCT07897721 | A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors | Pfizer | Phase 1 | Not yet recruiting | Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic... | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897721) |
| October 26, 2026 | NCT07894874 | A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. | InventisBio Yiqi Beijing Limited | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894874) |
| October 23, 2026 | NCT07892625 | A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 338 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892625) |
| October 22, 2026 | NCT07890246 | A Phase 1 Study of IM-1340 in Participants With Advanced Cancer | Immunome, Inc. | Phase 1 | Not yet recruiting | Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890246) |
| October 22, 2026 | NCT07887971 | A Study of \[225Ac\]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors | Aktis Oncology, Inc. | Phase 1 | Recruiting | NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate... | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887971) |
| October 21, 2026 | NCT07886229 | Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer | Second Xiangya Hospital of Central South University | Phase 1 | Recruiting | Resectable Non-Small-Cell Lung Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886229) |
| October 21, 2026 | NCT07886047 | Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer | Second Xiangya Hospital of Central South University | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886047) |
| October 6, 2026 | NCT07861425 | Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard... | Acepodia Biotech, Inc. | Phase 1 | Recruiting | Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861425) |
| October 5, 2026 | NCT07857616 | SI-B036-ST-101 in Advanced/Metastatic Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non... | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857616) |
| September 30, 2026 | NCT07848295 | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 | Not yet recruiting | Clear Cell Renal Cell Carcinoma (ccRCC) | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848295) |
| September 11, 2026 | NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant, Testicular Neoplasms, Lung Neoplasms... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815951) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 10 |
| Memorial Sloan Kettering Cancer Center | 9 |
| M.D. Anderson Cancer Center | 9 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 8 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 6 |
| Vanderbilt-Ingram Cancer Center | 5 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 5 |
| West China Hospital | 5 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 5 |
| SystImmune Inc. | 5 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 5 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 4 |
| City of Hope Medical Center | 4 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 4 |
| University of Pennsylvania | 3 |
| Myeloid Therapeutics | 3 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 3 |
| Emory University | 3 |
| University of California, Davis | 3 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 3 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 3 |
| Seattle Children's Hospital | 3 |
| Second Xiangya Hospital of Central South University | 3 |
| Sichuan University | 3 |

## By country

| Country | Trials |
| --- | --- |
| United States | 227 |
| China | 119 |
| Spain | 39 |
| Australia | 37 |
| France | 33 |
| South Korea | 31 |
| Canada | 30 |
| Japan | 25 |
| United Kingdom | 19 |
| Italy | 18 |
| Belgium | 15 |
| Germany | 13 |
| Taiwan | 12 |
| Netherlands | 12 |
| Israel | 10 |
| Poland | 8 |
| Denmark | 6 |
| Singapore | 6 |
| Switzerland | 5 |
| Georgia | 4 |
| Turkey (Türkiye) | 4 |
| Puerto Rico | 3 |
| Bulgaria | 3 |
| Sweden | 3 |
| Austria | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sign makers in the United States](https://specstream.ai/data/businesses/sign-makers/united-states)
- [Asian fusion restaurants in the United States](https://specstream.ai/data/businesses/asian-fusion-restaurants/united-states)
- [Damage restoration companies in the United States](https://specstream.ai/data/businesses/damage-restoration-companies/united-states)
- [HR services firms in the United States](https://specstream.ai/data/businesses/hr-services-firms/united-states)
- [Pediatric neurology practices in the United States](https://specstream.ai/data/businesses/pediatric-neurology-practices/united-states)
- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
